Pemetrexed safety and pharmacokinetics in patients with third-space fluid

Nicolas J Dickgreber, Jens Benn Sørensen, Luis G Paz-Ares, Tine Kjestrup Schytte, Jane E Latz, Karen B Schneck, Yuan Zheng, José Miguel Sanchez-Torres

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

27 Citationer (Scopus)

Abstract

Pemetrexed is established as first-line treatment with cisplatin for malignant pleural mesothelioma and advanced nonsquamous non-small-cell lung cancer (NSCLC) and as single-agent second-line treatment for nonsquamous NSCLC. Because the structure and pharmacokinetics of pemetrexed are similar to those of methotrexate, and methotrexate is associated with severe toxicity in patients with third-space fluid (TSF), the safety of pemetrexed in patients with TSF was evaluated.
OriginalsprogEngelsk
TidsskriftClinical Cancer Research
Vol/bind16
Udgave nummer10
Sider (fra-til)2872-80
Antal sider9
ISSN1078-0432
DOI
StatusUdgivet - 15 maj 2010

Citationsformater